Myo/Nog Cells Give Rise to Myofibroblasts During Epiretinal Membrane Formation in a Mouse Model of Proliferative Vitreoretinopathy.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 02 2023
Historique:
entrez: 1 2 2023
pubmed: 2 2 2023
medline: 4 2 2023
Statut: ppublish

Résumé

Myo/Nog cells are the source of myofibroblasts in the lens and synthesize muscle proteins in human epiretinal membranes (ERMs). In the current study, we examined the response of Myo/Nog cells during ERM formation in a mouse model of proliferative vitreoretinopathy (PVR). PVR was induced by intravitreal injections of gas and ARPE-19 cells. PVR grade was scored by fundus imaging, optical coherence tomography, and histology. Double label immunofluorescence localization was performed to quantify Myo/Nog cells, myofibroblasts, and leukocytes. Myo/Nog cells, identified by co-labeling with antibodies to brain-specific angiogenesis inhibitor 1 (BAI1) and Noggin, increased throughout the eye with induction of PVR and disease progression. They were present on the inner surface of the retina in grades 1/2 PVR and were the largest subpopulation of cells in grades 3 to 6 ERMs. All α-SMA-positive (+) cells and all but one striated myosin+ cell expressed BAI1 in grades 1 to 6 PVR. Folds and areas of retinal detachment were overlain by Myo/Nog cells containing muscle proteins. Low numbers of CD18, CD68, and CD45+ leukocytes were detected throughout the eye. Small subpopulations of BAI1+ cells expressed leukocyte markers. ARPE-19 cells were found in the vitreous but were rare in ERMs. Pigmented cells lacking Myo/Nog and muscle cell markers were present in ERMs and abundant within the retina by grade 5/6. Myo/Nog cells differentiate into myofibroblasts that appear to contract and produce retinal folds and detachment. Targeting BAI1 for Myo/Nog cell depletion may be a pharmacological approach to preventing and treating PVR.

Identifiants

pubmed: 36723927
pii: 2785323
doi: 10.1167/iovs.64.2.1
pmc: PMC9904330
doi:

Substances chimiques

Muscle Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1

Subventions

Organisme : NEI NIH HHS
ID : P30 EY001319
Pays : United States

Références

PLoS One. 2019 Apr 11;14(4):e0214758
pubmed: 30973903
Retina. 2015 Feb;35(2):165-75
pubmed: 25602631
Prog Retin Eye Res. 2002 Jan;21(1):127-44
pubmed: 11906814
Br J Ophthalmol. 2000 Nov;84(11):1306-11
pubmed: 11049960
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):650-61
pubmed: 18235011
Surv Ophthalmol. 1998 Jul-Aug;43(1):3-18
pubmed: 9716190
Ophthalmology. 1989 Jun;96(6):801-10
pubmed: 2662102
J Cell Biol. 2006 Oct 23;175(2):283-92
pubmed: 17060497
Tissue Antigens. 1992 Jul;40(1):13-21
pubmed: 1359668
Exp Dermatol. 2012 Jun;21(6):466-8
pubmed: 22621191
PLoS One. 2017 Jan 18;12(1):e0169744
pubmed: 28099524
Front Neurosci. 2021 Dec 07;15:780707
pubmed: 34949984
Vet Clin North Am Small Anim Pract. 1996 Sep;26(5):1043-64
pubmed: 8863390
Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1355-63
pubmed: 12601069
Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):347-57
pubmed: 24276562
PLoS One. 2020 Aug 24;15(8):e0235898
pubmed: 32833999
J Cell Biol. 2004 Mar 1;164(5):739-46
pubmed: 14981095
Sci Rep. 2021 Jul 20;11(1):14808
pubmed: 34285325
Arch Ophthalmol. 2004 Mar;122(3):406-8
pubmed: 15006864
Eye (Lond). 2020 Apr;34(4):616-631
pubmed: 31576027
Dev Biol. 2009 Dec 1;336(1):30-41
pubmed: 19778533
J Pharmacol Exp Ther. 2017 Apr;361(1):60-67
pubmed: 28096456
J Cell Physiol. 2014 Nov;229(11):1577-83
pubmed: 24604697
Br J Ophthalmol. 1990 Jul;74(7):393-9
pubmed: 2378854
Gene Expr Patterns. 2005 Feb;5(3):387-95
pubmed: 15661645
Transl Vis Sci Technol. 2020 Jun 05;9(7):9
pubmed: 32832216
Nat Protoc. 2007;2(1):67-77
pubmed: 17401340
Ophthalmology. 1989 Jun;96(6):811-20; discussion 821
pubmed: 2740079
Am J Ophthalmol. 1982 May;93(5):559-64
pubmed: 7081354
Exp Eye Res. 2016 May;146:22-25
pubmed: 26688580
Scand J Immunol. 2008 May;67(5):453-63
pubmed: 18405323
Curr Eye Res. 1996 Nov;15(11):1144-7
pubmed: 8950510
PLoS One. 2014 Apr 15;9(4):e95262
pubmed: 24736495
Exp Eye Res. 1996 Feb;62(2):155-69
pubmed: 8698076
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1813-1823
pubmed: 31042787
Exp Eye Res. 2009 Feb;88(2):257-69
pubmed: 19013456
Invest Ophthalmol Vis Sci. 1995 Feb;36(2):391-405
pubmed: 7531185
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):3940-3949
pubmed: 28777835
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1396-400
pubmed: 7877989
Surv Ophthalmol. 2013 Jul-Aug;58(4):321-9
pubmed: 23642514
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):740-52
pubmed: 8603859
Arch Ophthalmol. 1981 Aug;99(8):1445-54
pubmed: 7020665
J Cell Biol. 2001 Oct 29;155(3):381-92
pubmed: 11684706
Ophthalmology. 1989 Jun;96(6):835-41
pubmed: 2662103
Ophthalmologica. 2007;221(2):78-94
pubmed: 17380062
Dev Biol. 2011 Nov 1;359(1):12-25
pubmed: 21884693
Am J Ophthalmol. 1990 Dec 15;110(6):593-8
pubmed: 1701071
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2336-42
pubmed: 10892881
Clin Exp Ophthalmol. 2001 Feb;29(1):33-7
pubmed: 11272783
Mediators Inflamm. 2013;2013:269787
pubmed: 24198445
J Cell Biol. 2007 Aug 13;178(4):649-60
pubmed: 17698608
Nature. 2007 Nov 15;450(7168):430-4
pubmed: 17960134
Int Ophthalmol Clin. 2019 Winter;59(1):221-240
pubmed: 30585928
PLoS One. 2020 Jul 2;15(7):e0234792
pubmed: 32614850
J Ocul Pharmacol Ther. 2013 Apr;29(3):310-8
pubmed: 23116162
Curr Opin Ophthalmol. 2022 May 1;33(3):219-227
pubmed: 35220328
Compr Ophthalmol Update. 2006 Jul-Aug;7(4):179-85
pubmed: 17007731
Ophthalmology. 1987 Apr;94(4):327-32
pubmed: 3587912
Mol Vis. 2011;17:1794-805
pubmed: 21750605
Brain Behav Immun. 2011 Jul;25(5):915-21
pubmed: 20888903
Immunol Lett. 2018 Apr;196:22-32
pubmed: 29366662
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14833-8
pubmed: 8962141
Invest Ophthalmol Vis Sci. 1990 Dec;31(12):2529-45
pubmed: 1702409
Acta Ophthalmol. 2022 Dec;100(8):e1767-e1768
pubmed: 35225433
Ophthalmic Res. 2018;60(4):195-204
pubmed: 29723860
Exp Eye Res. 2018 Jun;171:101-105
pubmed: 29559302
J Cell Biol. 2000 May 15;149(4):825-34
pubmed: 10811824
Nature. 2013 May 9;497(7448):263-7
pubmed: 23615608
Exp Eye Res. 2020 Aug;197:108080
pubmed: 32474138
Prog Retin Eye Res. 1998 Jan;17(1):77-98
pubmed: 9537796

Auteurs

Mara Crispin (M)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Jacquelyn Gerhart (J)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Alison Heffer (A)

Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States.

Mark Martin (M)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Fathma Abdalla (F)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Arturo Bravo-Nuevo (A)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Nancy J Philp (NJ)

Sydney Kimmel Medical School of Thomas Jefferson University, Philadelphia, Pennsylvania, United States.

Ajay E Kuriyan (AE)

Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States.
Current address: Retina Service/Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.

Mindy George-Weinstein (M)

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH